Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

Ítems similars

• Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
  per: Kloess, Stephan, et al.
  Publicat: (2017)
• Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia
  per: Vyas, Maulik, et al.
  Publicat: (2016)
• Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering
  per: Oberschmidt, Olaf, et al.
  Publicat: (2019)
• Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids
  per: Klöss, Stephan, et al.
  Publicat: (2015)
• DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies
  per: Shatnyeva, Olga M., et al.
  Publicat: (2015)